- Source: PF-219,061
PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction. It did not advance into clinical trials.
See also
ABT-670
ABT-724
Cabergoline
Bremelanotide
Flibanserin
Intrinsa
Melanotan II
OSU-6162
PF-592,379
Pramipexole
Tibolone
UK-414,495